R&D Changing the drug development treatment paradigm: Hilary Eat... Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.
R&D Increasing trial efficiency: Adityo Prakash talks small data... Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.
R&D Immune mediation, B-cell depletion, and female leadership – ... In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
R&D Maximising value by uniting the digital backbone: On a new N... Novo Nordisk and Veeva have entered into a new partnership for clinical development.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
News Anavex sinks after pulling Alzheimer's filing in EU Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer's therapy.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.